Deliberations more than a cut‐off HBsAg value for Nuc cessation: Authors’ Reply

Abstract

We read the comments by Jeng WJ, et al. with great interest and would like to clarify a few issues raised on our systematic review.⁽¹⁾

We didn't include the study of Wang CC AJG 2016 and Tseng CH J Formos Med Assoc 2018 for unavailable relapse data in the setting of different HBsAg levels at the end of treatment (EOT). We also excluded the study of Hsu YC CGH 2016 because only minimum entecavir treatment time was emphasized without consideration of consolidation therapy after achieving HBeAg seroconversion or undetectable HBV DNA when patients discontinued entecavir. Chen CH, et al.

This article is protected by copyright. All rights reserved.

http://bit.ly/2SVMUYj